CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 4 of the 11 sources its claims cite were checked for support.

Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii

Open access

Abstract

The inner membrane complex (IMC) of Toxoplasma gondii as a peripheral membrane system has unique and critical roles in parasite replication, motility and invasion. Disruption of IMC sub-compartment protein produces a severe defect in T. gondii endodyogeny, the form of internal cell budding. In this study, we generated T. gondii virus-like particle particles (VLPs) containing proteins derived from IMC, and investigated their efficacy as a vaccine in mice. VLP vaccination induced Toxoplasma gondii-specific total IgG, IgG1 and IgG2a antibody responses in the sera and IgA antibody responses in the feces. Upon challenge infection with a lethal dose of T. gondii (ME49), all vaccinated mice survived, whereas all naïve control mice died. Vaccinated mice showed significantly reduced cyst load and cyst size in the brain. VLP vaccination also induced IgA and IgG antibody responses in feces and intestines, and antibody-secreting plasma cells, mixed Th1/Th2 cytokines and CD4+/CD8+ T cells from spleen. Taken together, these results indicate that non-replicating VLPs containing inner membrane complex of T. gondii represent a promising strategy for the development of a safe and effective vaccine to control the spread of Toxoplasma gondii infection.

Overview

CoChat Summary

## TL;DR

This mouse study tested a virus-like particle (VLP) vaccine carrying *Toxoplasma gondii* inner membrane complex proteins and found strong systemic and mucosal immune responses. Vaccinated mice survived a lethal challenge and had reduced brain cyst burden, suggesting the VLP platform is a promising vaccine candidate.

## Key findings

  • Intranasal vaccination with the VLPs induced *T. gondii*-specific serum antibodies: total IgG, IgG1, and IgG2a, plus mucosal IgA in feces.
  • After challenge with *T. gondii* ME49, vaccinated mice had significantly higher antibody responses in serum, feces, and intestines; the paper reports *P* < 0.05 for these increases.
  • Vaccination reduced brain parasite burden: cyst count and cyst size were significantly decreased, with a reported reduction rate of 65%.
  • Protection was strong: all vaccinated mice survived a lethal challenge with 120 cysts, while all naïve control mice died; in the 30-cyst challenge, vaccinated mice had 100% survival and controls had 60% survival.

## Methods

  • Design: preclinical mouse vaccination-challenge study using non-replicating VLPs displaying *T. gondii* IMC protein with influenza M1 as core protein.
  • Sample/sample size: female BALB/c mice, 6–8 weeks old; groups of *n* = 6 per group.
  • Main analysis: mice were intranasally immunized twice with 100 μg total VLP protein at 4-week intervals, then orally challenged with *T. gondii* ME49 (30 or 120 cysts); outcomes included ELISA for IgG/IgG1/IgG2a/IgA, brain cyst counts and size, survival, body weight, ASC assays, cytokines (IFN-γ, IL-6, IL-10), and CD4+/CD8+ T cells.

## Limitations

  • The paper states that there is no standard protocol for evaluating *T. gondii* vaccines in animal models, so the challenge isolate and dose vary across studies.
  • Evident from the text: the study is limited to mice and does not test human efficacy or safety.
  • Evident from the text: the paper does not report long-term protection beyond the 1-month postchallenge assessments described.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0161231

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Construction of pFastBac vectors. (A) Toxoplasma gondii IMC gene was PCR-amplified from cDNA synthesized using a Prime Script 1st Strain CDNA Synthesis Kit using total RNA extracted from T. gondii RH. M denotes DNA marker and lane 1 indicates amplified PCR product. (B) Influenza M1 gene was PCR amplified from total RNA extracted from influenza virus (A/PR/8/34). M denotes DNA marker and lane 2 indicates amplified PCR product. (C and D) Toxoplasma gondii IMC gene and influenza M1 gene were cloned in to pFastBac with EcoRI / XhoI and EcoRI / XhoI enzymes, respectively, resulting in T. gondii IMC plasmid (C) and M1 plasmid (D).
Fig 1 Construction of pFastBac vectors. (A) Toxoplasma gondii IMC gene was PCR-amplified from cDNA synthesized using a Prime Script 1st Strain CDNA Synthesis Kit using total RNA extracted from T. gondii RH. M denotes DNA marker and lane 1 indicates amplified PCR product. (B) Influenza M1 gene was PCR amplified from total RNA extracted from influenza virus (A/PR/8/34). M denotes DNA marker and lane 2 indicates amplified PCR product. (C and D) Toxoplasma gondii IMC gene and influenza M1 gene were cloned in to pFastBac with EcoRI / XhoI and EcoRI / XhoI enzymes, respectively, resulting in T. gondii IMC plasmid (C) and M1 plasmid (D).CC BY · PubMed Central
Fig 2 Characterization of virus-like particles (VLPs). (A) Normal SF9 cells. (B) VLP-producing cells. (C) Electron microscopy and (D) VLP size determination. Negative staining of VLPs was performed followed by transmission electron microscopy. The size is between 40 and 120 nm. (E) Western blot analysis. VLPs (20, 10, 5 μg) were loaded for SDS-PAGE. Polyclonal mouse anti-T. gondii antibody was used to probe T. gondii IMC protein (18kD) and anti-M1 monoclonal antibody was used to determine influenza M1 protein (28kD).
Fig 2 Characterization of virus-like particles (VLPs). (A) Normal SF9 cells. (B) VLP-producing cells. (C) Electron microscopy and (D) VLP size determination. Negative staining of VLPs was performed followed by transmission electron microscopy. The size is between 40 and 120 nm. (E) Western blot analysis. VLPs (20, 10, 5 μg) were loaded for SDS-PAGE. Polyclonal mouse anti-T. gondii antibody was used to probe T. gondii IMC protein (18kD) and anti-M1 monoclonal antibody was used to determine influenza M1 protein (28kD).CC BY · PubMed Central
Fig 3 Toxoplasma gondii-specific antibodies responses upon immunization. Mice were immunized twice with VLPs as indicated with a 4-week interval. T. gondii-specific IgG, IgG1 and IgG2a antibody responses in the sera were determined after prime and boost (A-C). T. gondii-specific IgG and IgA antibody responses in the feces were determined (D and E). Imm: immunization
Fig 3 Toxoplasma gondii-specific antibodies responses upon immunization. Mice were immunized twice with VLPs as indicated with a 4-week interval. T. gondii-specific IgG, IgG1 and IgG2a antibody responses in the sera were determined after prime and boost (A-C). T. gondii-specific IgG and IgA antibody responses in the feces were determined (D and E). Imm: immunizationCC BY · PubMed Central
Fig 4 Toxoplasma gondii-specific antibodies responses upon challenge infection. Immunized mice were challenge infected orally with T. gondii ME49 at week 4 after boost and T. gondii-specific IgG (A), IgG1 (B) and IgG2a (C) antibody responses in the sera were determined (A-C; mean±SD, *P < 0.05). IgA and IgG antibody responses from feces and intestine were also determined at week 4 postchallenge (D-G; mean±SD, *P < 0.05). Cha: challenge infection
Fig 4 Toxoplasma gondii-specific antibodies responses upon challenge infection. Immunized mice were challenge infected orally with T. gondii ME49 at week 4 after boost and T. gondii-specific IgG (A), IgG1 (B) and IgG2a (C) antibody responses in the sera were determined (A-C; mean±SD, *P < 0.05). IgA and IgG antibody responses from feces and intestine were also determined at week 4 postchallenge (D-G; mean±SD, *P < 0.05). Cha: challenge infectionCC BY · PubMed Central
Fig 5 Protections against T. gondii (ME49) challenge infection. Immunized mice were challenge infected orally with T. gondii (ME49) with a lethal dose (120 cysts) or low dose (30 cysts) at week 4 after boost. The experiment was repeated twice. For a low dose challenge experiment, mice were sacrificed and cyst counts (A) and cyst sizes (B) in brain were determined at week 4 after challenge infections (mean±SD, *P < 0.05, *P < 0.05). Body weight changes and survival were also determined daily upon challenge infection (C and D). For a lethal dose challenge experiment, mice were monitored daily to determine body weight changes and survival (E and F). Upon the lethal dose challenge infection (120 cysts), all vaccinated mice survived without significant decrease of body weight, whereas all naïve control mice died with a significant and progressive loss in body weight (E and F).
Fig 5 Protections against T. gondii (ME49) challenge infection. Immunized mice were challenge infected orally with T. gondii (ME49) with a lethal dose (120 cysts) or low dose (30 cysts) at week 4 after boost. The experiment was repeated twice. For a low dose challenge experiment, mice were sacrificed and cyst counts (A) and cyst sizes (B) in brain were determined at week 4 after challenge infections (mean±SD, *P < 0.05, *P < 0.05). Body weight changes and survival were also determined daily upon challenge infection (C and D). For a lethal dose challenge experiment, mice were monitored daily to determine body weight changes and survival (E and F). Upon the lethal dose challenge infection (120 cysts), all vaccinated mice survived without significant decrease of body weight, whereas all naïve control mice died with a significant and progressive loss in body weight (E and F).CC BY · PubMed Central
Fig 6 Antibody secreting cell responses. Immunized mice were challenge infected with T. gondii (ME 49) at week 4 after boost and antibody-secreting cells (ASC) in the spleen were determined at week 4 after challenge infections. IgG, IgG1, IgG2a and IgA-secreting cell responses were seen as indicated (A-D; mean±SD, *P < 0.05).
Fig 6 Antibody secreting cell responses. Immunized mice were challenge infected with T. gondii (ME 49) at week 4 after boost and antibody-secreting cells (ASC) in the spleen were determined at week 4 after challenge infections. IgG, IgG1, IgG2a and IgA-secreting cell responses were seen as indicated (A-D; mean±SD, *P < 0.05).CC BY · PubMed Central
Fig 7 T cell responses. Immunized mice were challenge infected and at week 4 after challenge infections mice were sacrificed. IFN-γ, IL-4 and IL-6 cytokines (A-C), and CD4+ T cell and CD8+ T cell populations in the spleen were determined (D and E; mean±SD, *P<0.05).
Fig 7 T cell responses. Immunized mice were challenge infected and at week 4 after challenge infections mice were sacrificed. IFN-γ, IL-4 and IL-6 cytokines (A-C), and CD4+ T cell and CD8+ T cell populations in the spleen were determined (D and E; mean±SD, *P<0.05).CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 6 Not checked · 44 Own results and interpretations

32 more claims

Create a free account to see all 54 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 9
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 27 references

Cited by

See all 36

Metadata

Authors
Lee, D. H., Lee, S. H., Kim, A. R., & Quan, F. S.
Affiliations
Kyung Hee University (KR)
Corresponding author
Quan, Fu Shi
Venue
PLOS ONE
Published
2016-08-22
Volume
11
Issue
8
Pages
e0161231
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2517189574
Cited by
36
References
27
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 4
FWCI
4.47
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation of Korea (NRF-2014R1A2A2A01004899)
  • Rural Development Administration (315030031-HD020)
  • Ministry of Health and Welfare (HI15C2928)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
  • Life Sciences › Immunology and Microbiology › Parasitology › Parasitic infections in humans and animals
Keywords
Toxoplasma gondii, toxoplasmosis vaccine, virus-like particles, inner membrane complex, endodyogeny, antibody response, IgA, IgG, Th1/Th2 cytokines, CD4+CD8+ T cells, ME49 strain, non-replicating vaccine
MeSH terms
Animals, Antibodies, Protozoan, Brain, Feces, Female, Immunoglobulin A, Immunoglobulin G, Intestines, Mice, Inbred C57BL, Toxoplasma, Toxoplasmosis, Animal, Vaccination, Protozoan Proteins, Survival Analysis, Protozoan Vaccines, CD4-CD8 Ratio, Mice, Nanoparticles, Th1-Th2 Balance, Vaccines, Virus-Like Particle

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii. https://app.cochat.ai/papers/10.1371/journal.pone.0161231
The paper
Lee, D. H., Lee, S. H., Kim, A. R., & Quan, F. S. (2016). Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii. PLOS ONE. https://doi.org/10.1371/journal.pone.0161231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.